Themis Medicare Boosts Warrant Price to ₹102.87, Eyes Up to 4.99% Shareholder Dilution

Themis Medicare's Preferential Issue Committee has approved a revised issue price of Rs. 102.87 per Convertible Equity Warrant, an increase from the previously considered Rs. 100. This adjustment is part of a preferential issue to Vividhmargi Investments Private Limited.

The proposed issuance could lead to a dilution of up to 4.99% in the company's total shareholding, with approximately 45,95,795 warrants potentially converting into equity shares. The final amount raised will be determined at the time of allotment, subject to necessary shareholder and stock exchange approvals.

Reader Takeaway: Higher warrant price signals fundraising push; 4.99% dilution looms amid ongoing financial pressures.

What just happened (today’s filing)

Themis Medicare's Preferential Issue Committee met on March 10, 2026, to approve a revised issue price for convertible equity warrants. The new price is set at Rs. 102.87 per warrant, up from Rs. 100 per warrant previously considered.

This preferential issue is intended for Vividhmargi Investments Private Limited and represents a potential dilution of up to 4.99% of the company's total share capital. The total value of the issue is yet to be finalized upon allotment.

The committee's decision builds upon the board's earlier approval from February 13, 2026, and the committee's specific approval on February 25, 2026, for the same warrants at the lower price.

Why this matters

This move signals Themis Medicare's ongoing effort to raise capital, likely for working capital needs or general corporate purposes, as indicated in previous disclosures related to warrant issuances. The revised, higher price might reflect market conditions or the company's valuation, while the potential dilution directly affects existing shareholders' ownership percentages.

The backstory (grounded)

This is not the first attempt by Themis Medicare to issue warrants to Vividhmargi Investments. On February 25, 2026, the company had approved the allotment of the same number of warrants (45,95,795) at Rs. 100 each. Vividhmargi Investments is already a significant shareholder, holding about 15.78% as of June 2025.

However, the company's financial health presents a challenging backdrop. Recent reports indicate contracting net sales and net losses, coupled with a substantially negative operating profit CAGR of approximately -189.22% over the last five years, suggesting persistent operational difficulties. The stock has also faced negative sentiment, flagged as 'Expensive Valuation' and 'Technically Bearish' in early 2026, with promoters pledging 2.43% of their shares.

What changes now

Upon successful completion of the preferential issue and conversion of warrants, Themis Medicare's equity share capital will increase, leading to dilution for existing shareholders.

The funds raised are expected to bolster the company's financial resources, potentially aiding its working capital or general corporate needs.

This event could alter the company's capital structure, though the full financial impact depends on the final amount raised and its application.

Risks to watch

Shareholder and stock exchange approvals are critical next steps; without them, the issuance cannot proceed.

The total value of the preferential issue remains undetermined, which adds an element of uncertainty until the allotment is finalized.

The company's history of financial difficulties, including net losses and a negative operating profit CAGR, remains a significant concern, despite the capital infusion.

Peer comparison

Preferential issues are a common fundraising route in the Indian pharmaceutical sector. Companies like Bajaj Healthcare, Granules India, and Prism Medico and Pharmacy have recently engaged in similar fundraising activities through preferential allotments and warrant issuances to secure capital for their growth strategies.

Context metrics (time-bound)

• Promoter holding was approximately 67.11% as of December 2025.
• Promoters had pledged 2.43% of their holdings as of December 2025.

What to track next

• The outcome of the upcoming shareholder approval process (postal ballot).
• Final approval from the BSE and NSE for the preferential issue.
• The announcement of the total amount raised upon the final allotment of warrants.
• The company's subsequent financial performance and operational improvements.